These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 27422935

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y, Onishi H, Nambu A, Araki T.
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [Abstract] [Full Text] [Related]

  • 3. 18F-FDG PET/CT quantitative parameters as prognostic factor in localized and inoperable lung cancer.
    Infante JR, Cabrera J, Rayo JI, Cruz C, Serrano J, Moreno M, Martínez A, Jiménez P, Cobo A.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Jan; 39(6):353-359. PubMed ID: 32605894
    [Abstract] [Full Text] [Related]

  • 4. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
    Takeda K, Takanami K, Shirata Y, Yamamoto T, Takahashi N, Ito K, Takase K, Jingu K.
    J Radiat Res; 2017 Nov 01; 58(6):862-869. PubMed ID: 29036692
    [Abstract] [Full Text] [Related]

  • 5. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P, Janvary ZL, Coucke P, Jodogne S, Bernard C, Hatt M, Visvikis D, Jansen N, Duysinx B, Hustinx R.
    Eur J Nucl Med Mol Imaging; 2016 Jul 01; 43(8):1453-60. PubMed ID: 26830299
    [Abstract] [Full Text] [Related]

  • 6. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, Pandey AK, Sekhar Bal C, Patel CD, Sharma P, Agarwal KK, Kumar R.
    Clin Nucl Med; 2018 Jan 01; 43(1):e8-e17. PubMed ID: 29112011
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH.
    Nucl Med Commun; 2013 Oct 01; 34(10):959-63. PubMed ID: 23921784
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb 01; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY, Guo Z, Sun J, Yang WP, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2018 Jul 23; 40(7):528-533. PubMed ID: 30060362
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y, Lin WY, Kao CH, Yen KY, Chen SW, Yeh JJ.
    Anticancer Res; 2012 Nov 23; 32(11):5087-91. PubMed ID: 23155285
    [Abstract] [Full Text] [Related]

  • 19. Metabolic tumor volume derived from 18F-FDG PET/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients.
    Ding C, Mao X, Li N, Huang M, Huang Z, Bao W, Li H, Fan J.
    Hell J Nucl Med; 2022 Nov 23; 25(1):63-70. PubMed ID: 35503557
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.